Novo Nordisk launched his blockbuster weight loss on Tuesday, Semaglutide, before the next year patent expansion that will record the generic versions of the flooding Indian market.
Wegovy is a glucagonian peptide-1 receptor agonist (GLP-1), which is indicated in India for weight management and reduce the risk of large adverse cardiovascular events.
The medicine will be available in a device filled with a pen in five doses-starting with 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dose of 2.4 mg. The first three doses are prices £4 336 for one dose and £17 345 per month, while a dose of 1.7 mg is the price per £24 280 per month and 2.4 mg per £26 015 per month.
Read also: Ozem patent, patent challenge and plant $ 25 billion for the Indian drug market for weight loss
Wegovy is an injection once a week that monitors the monthly batch cycle. It starts with the smallest dose of 0.25 mg and gradually increases to higher doses each month. Once the patient is given a dosage of 1 mg, the physician assesses the need to further increase, maintain or reduce it depending on the outcome.
The drug is expected to be in pharmacies by the end of the month, said Novo Nordisk India Vikrant Shrotriya.
The company launched a month after the opponent Eli Lilly launched his injection loss in Mounjaro (Tirzepatide) in March 2025. £14 000 per month for a bottle with 2.5 mg and £17 500 per month for 5 mg bottle.
Novo Nordisk also faces loss of patent protection for Semaglutid, Wegovey compound, in March 2026. Mint announced last week as several Indian drug manufacturers are preparing to start cheaper generic versions of cash on the $ 25 weight loss market.
Read also: As the Ozemian creator lost the adhesion of the obesity market that he created
Despite the competition of Eli Lilly, the early advantage of the tractor and future competition from cheaper generics, Shrotriya said in an interview that Novo Nordisk is banking on his furnishings filled with pen and insulin management in India to gain a strong market share.
“We have served this market for so long … So we have won this kind of rumor that we are a trusted partner,” Shrotriya said. “And this goes a long way to settle in this new therapeutic area, which is obesity,” he added.
Novo Nordisk has more than half of the market share in India £4,400 markets of insulin crore.
Wegovy will be distributed to the Indian market in cooperation with Abbott, who is also a distribution partner for other brands Novo Nordisk in the country.
Indian market potential
Shrotriya said that the company is looking at the start of Pan-India for Wegovy and ensuring that it has the ability to satisfy demand.
According to a study of the Indian Council for Medical Research in Indian Research (ICMR-India), India has 254 million people with generalized obesity and 351 million people with abdominal obesity in India.
Read also: Do not use Mounjaro as a way of skinny: Dr. Alexander Sowa
According to Nuvama research, the weight loss market will be $ 25 billion in 2024 and could be doubled by 2033. Economic times on Tuesday reported people with knowledge of the matter that the company focuses $ 1 billion from the sale of Wegovy in India in the next 5-7 years.
The high expectations of sales only emphasize the opportunity in the Indian drug market that are still covered by patents. Previously, multinational companies would not be subject to the priority of drug starting in India and quoted availability as a criterion. Drugs like Weg could change it.
(Tagstotranslate) Novo Nordisk India (T) Eli Lilly (T) Injection Mounjaro (T) Semaglutide (T) Indian Tregmakers
